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Malignant melanoma is a serious disease in both humans and dogs, and the high
metastatic potential results in poor prognosis for many patients. Its similarities with human
melanoma make spontaneous canine melanoma an excellent model for comparative
studies of novel therapies and tumor biology. Gene therapy using adenoviruses encoding
the immunostimulatory gene CD40L (AdCD40L) has shown promise in initial clinical trials
enrolling human patients with various malignancies including melanoma. We report a
study of local AdCD40L treatment in 32 cases of canine melanoma (23 oral, 5 cutaneous,
3 ungual and 1 conjunctival). Eight patients were World Health Organization (WHO)
stage I, 9 were stage II, 12 stage III, and 3 stage IV. One to six intratumoral injections
of AdCD40L were given every seven days, combined with cytoreductive surgery in 20
cases and only immunotherapy in 12 cases. Tumor tissue was infiltrated with T and B
lymphocytes after treatment, suggesting immune stimulation. The best overall response
based on result of immunotherapy included 7 complete responses, 5 partial responses,
5 stable and 2 progressive disease statuses according to the World Health Organization
response criteria. Median survival was 285 days (range 20–3435 d). Our results suggest
that local AdCD40L therapy is safe and could have beneficial effects in dogs, supporting
further treatment development. Clinical translation to human patients is ongoing.
Keywords: immuno oncology, adenoviral vectors, translational medicine, canine malignant melanoma, clinical
trials, AdCD40L
INTRODUCTION
Canine melanoma is a cancer presenting in many different forms, each with different prognosis,
just like its human counterpart. Prognosis is dependent on anatomical location, stage at clinical
presentation and histologic grade. Oral and digital (ungual) malignant melanomas carry the worst
prognosis with a metastatic rate ranging from 40 to 100% at initial diagnosis and a median overall
survival (OS) after radical surgery of less than five months (1–3). Cell proliferation is reported to
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predict survival and a mitotic index >2 is considered of
prognostic significance (3). In contrast to humans, where most
melanomas in the skin are classified as a skin cancer (4),
only about 20% of dermal melanomas in dogs are malignant,
but the high-grade types still result in a poor prognosis.
Ocular melanomas are in general benign, with a few important
exceptions where severe aggressive behavior can be seen, and
also here mitotic index seems the most reliable prognostic
indicator (5, 6). Histological grade, in particular nuclear atypia
and proliferation index using Ki-67, has been shown to correlate
to prognosis (7, 8). Median survival times for dogs with oral
melanoma treated with surgery are approximately 17–18, 5–
6, and 3 months with stage I, II, and III disease, respectively,
clearly indicating that there is an unmet need for developing
adjuvant treatment modalities in high-stage disease. Aggressive
facial and digital surgery in dogs can severely influence normal
function and quality of life post-operatively. A multimodal
therapy approach can therefore contribute to decreased surgical
intensity, while still extending overall survival with fewer adverse
events, for improved animal welfare. Spontaneous models of
tumors in pet dogs have been receiving increased attention as
a comparative asset for many cancers in humans, including
malignant melanoma (9–11).
Immune evasion is one hallmark of cancer and is identified
in both human and canine malignant melanomas (12–14).
Several mechanisms are involved in this process, including T
regulatory (Treg) cell expansion, myeloid derived suppressor
cells, (MDSC), M2 tumor-promoting macrophage switch
and immunosuppressive cancer-derived exosomes (15, 16).
Immunoediting is a stepwise process and can be evolved over
several years (17). In general, the cancer tries to induce and
maintain a chronic inflammatory state and suppress signals
and pathways, creating an acute inflammatory environment
(18, 19). The role of dendritic cells is crucial for genesis and
maintenance of the tumor (20). CD40 is a co-stimulatory
molecule belonging to the tumor necrosis factor superfamily
and is essential in activation of dendritic cells (21). In many
tumors this expression is suppressed and the dendritic cells
are inactivated (22). Hence, reactivation of dendritic cells with
CD40 upregulation is an attractive strategy in immunotherapy
of different tumor models in vitro, in animal models and in
human clinical trials. Adenoviral cancer therapy has long been
recognized as a promising approach and has developed from
monotherapy gene transfer into a combinational approach.
Here oncolytic genetically modified adenoviral systems generate
neoantigen exposure to the tumor-associated immune system.
The transgene product simultaneously activates the immune
system suppressed by the tumor. Adenoviral cancer therapy is
generally seen as an attractive system because of low toxicity
with a convenient and reliable system of gene editing and gene
expression, and was the first viral vector developed for gene
therapy, being approved for clinical trials in 1990 (23). Even if
only a small part of the tumor becomes infected, the cascade
developed in the tumor can still be sufficient to induce a tumor
response as well as creating tumor-specific immune cells that can
move away from the treated tumor and seek and destroy cancer
cells in other locations, and hence an abscopal effect is generated.
Malignant melanoma in humans (HMM) often occurs in the
skin, but it originates from the neural crest; hence malignant
melanoma also can occur on mucous membranes and in the
gastro-intestinal canal, as well as the CNS, here primarily as
metastases. Local low-stage disease has an excellent prognosis,
whilst the 10-year survival in stage IV melanoma is only 10%.
Canine malignant melanomas are in many aspects suggested as
a good comparative model to HMM, particularly the rare non-
UV-induced human melanomas, especially mucosal melanomas
(10). In vitro stimulation in malignant melanomas as well as
intratumoral activation of CD40 in melanoma in mouse models
have shown promising results (24, 25). Two earlier studies
of replication-deficient AdCD40L intratumoral treatment of
spontaneous canine malignant melanoma have been reported
(26, 27). Hence, the rationale is obvious for perusing human
malignant melanoma in a clinical setting (28, 29).
The aim of this current study was to include a larger number
of dogs than previously reported, and with a life-long follow-up,
to present survival data and finally identify long-term effects of
episomal CD40L gene therapy.
MATERIALS AND METHODS
Study Design
This is a long-term follow-up study of a pilot study
using AdCD40L immunotherapy. In addition to the 19
previously reported dogs (26), 13 additional dogs were
added and all dogs were followed up until death. This
data was collected by contacting the dogs’ owners, as well
as retrieving individual patient information available in
the electronical medical record system (Trofast, Sanimalis,
Sweden) at the University Animal Hospital UDS, SLU.
Owners were asked for the date on which their dog
passed away/was euthanized, the reason for ultimate
euthanasia, and if recurrence of melanoma was known to
have occurred.
Between May 2005 and May 2013, 32 client-owned
dogs with spontaneously occurring malignant melanoma
participated in a study of local intratumoral AdCD40L
immunotherapy. AdCD40L therapy and sample collection
were approved by the Swedish Animal Ethical Committee
and the Swedish Animal Welfare Agency (C228/6). A
written consent form from the dog owners was obtained.
The therapy was performed within the University Animal
Hospital (UDS), at the Swedish University of Agricultural
Sciences (SLU).
Dogs were treated with weekly intratumoral and/or metastatic
lymph node injections (n = 1–6) of a human adenovirus
serotype 5 carrying a human CD40 ligand administered under
subcutaneous sedation with medetomidine/butorphanol (0.01
mg/0.1 mg/kg), with local lidocaine (100 mg/ml) anesthetic
spray for oral treatments. All sedated animals were reverted
with intramuscular injection of atipamezole (0.05 mg/kg) post
AdCD40L injection.
At each treatment, blood samples were collected; CBC,
standard clinical chemistry profile, and immunoglobulin
gel electrophoresis were performed. The AdCD40L vector
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was prepared by diluting 37 µl of stem solution (viral
titer 7 × 1010 Pfu/ml) to a volume of 1ml (2.6 × 109
Pfu) with sterile isotonic sodium chloride. This GMP-
produced AdCD40L was constructed at Baylor College
of Medicine, Huston, TX, USA and full description of
the virus is described in (30). Between 1ml and 3ml
AdCD40L were injected each time using a syringe and a
25-gauge needle.
Being a toxicity study on AdCD40L administration in dogs
with high stage/high grade malignant melanomas, initial dogs
started on low doses and few injections, carefully increasing the
dose (volume and titer) to monitor any toxicity. As the toxicity
did not differ between 0.5 and 3ml, it was decided to standardize
the dosing regimen to 1.0ml x 3. Exceptions were made where
owners insisted to have additional treatments as the vaccine had
a positive effect on tumor burden and quality of life. After an
initial dose-escalation phase, the suggested dose (1 ml−2.6 ×
109 Pfu), was considered optimized, as a larger volume could
be difficult to administered in smaller lesions. The protocol also
is analog to human trials, where the final selected dose is used,
regardless on tumor size or weight of the patient. In some trials,
the full dose is given in one selected lesion and in other protocols
the dose can be diluted and divided into several lesions. In our
study, a split dose regime was used. Hence, the dose volume
was adjusted with dilution buffer to render the same injection
volume per tumor lesion for split dose treatments as for full
dose treatment. Detailed information on oncolytic viral dose
calculation in human malignant melanoma is described in (31).
Although, the study is using a conditionally replicative oncolytic
herpes virus, it is still instructive and pivotal in explaining
principles in dose calculation regardless of tumor or patient size
and is the first FDA approved oncolytic virus therapy for human
refractory melanoma (T-VEC, or Imlygic R©).
Tumor tissues sampled pre- and post-treatment were
investigated for immune cell infiltration in 20 of the dogs.
Histological staining was performed according to the method
described previously (27). Briefly, tumor specimens were
fixed in a buffered 10% paraformaldehyde solution and
paraffin embedded. Tissue sections were prepared from
the paraffin-embedded tissues for routine hematoxylin-
eosin staining and immunohistochemistry and subjected to
staining procedures with either monoclonal mouse anti-human
CD3 (clone F7.2.38, DakoCytomation, Glostrup, Denmark)
or monoclonal mouse anti-human CD79 α (clone HM57,
DakoCytomation). The complex expressions were visualized
by using the DakoCytomation EnVision+R system HRP anti-
mouse (K 4001) with diaminobenzidine as substrate. Nuclear
counterstaining was performed with Mayer’s hematoxylin.
Investigations were done according to histologic remission and
immune cell infiltration. Briefly, histologic remission means less
viable tumor cells present after treatment and histologic complete
remission—that is, no tumor cells present post treatment (or post
mortem). Immune cell infiltration was graded 0–3, with 3 being
the highest grade of infiltration. Macroscopic tumor immune
reaction was clinical observation of swelling at the injection
site, ulceration and regional lymphadenopathy occurring days
post immunotherapy.
Clinical Assessment of Response
Response to therapy was categorized in accordance with
WHO criteria, where the products of bidimensional lesion
measurements are summed and the change is calculated from
baseline while on therapy in order to quantify response
(32). More specific CR is specified as complete regression of
measurable soft tissue disease, PR (partial regression, >50% but
<100% regression in one dimension of measurable soft tissue
disease), SD (stable disease,≤50% regression of soft tissue disease
or ≤25% progression), and PD (progressive disease, >25%
increase in measurable disease or appearance of new lesions).
The minimal time interval required between two measurements
for determination of stable disease response was 6 weeks. Best
overall response was defined as the best response recorded from
the start of the treatment until disease progression or recurrence.
Macroscopic tumor lesions were measured by digital caliper
and documented with photography (Figure 1). In addition, dogs
were followed with diagnostic imaging (computer tomography,
radiography and/or ultrasound), using the best suitable modality
for each case. Treatment adverse events were graded according to
the VCOG-CTCAE, version 1.1 (33).
Ultrasound was used very infrequent to follow tumor response
(most commonly to follow non-target lesions or for staging
purposes) and used only if any other modality was considered
inappropriate. If used, the guidelines described in (34) was used,
and more specific, the same machine and operator performed
all examinations for the individual patient. Dogs were rechecked
for as long as clinically necessary to determine survival for each
dog. Overall survival was defined as the time from first treatment
with AdCD40L until subsequent death. All dogs were followed
up until death.
Statistical Analyses
Survival-time distributions were estimated using the Kaplan–
Meier method. Statistical analyses were carried out using JMP
Pro 15.2.1 (SAS Institute Inc., Cary, NC) statistical discovery
software. Univariate survival analysis was carried out for each
parameter. Parameters determined to be of statistical significance
in the univariate analysis according to log-rank testing were
used to stratify Cox proportional hazard models. Parameters
included in this study were weight, sex, breed, WHO stage,
melanotic vs. amelanotic primary tumor, primary tumor location,
presence of local or/and distant metastases, number of AdCD40L
treatments, adverse effects after treatment, response, surgery
after treatment initiation, histologic tumor type and grade. A
parameter with a P-value < 0.05 was considered significant.
Adjusting for multiple testing was performed by Bonferroni
correction (35). The Bonferroni correction compensates for that
increase by testing each individual hypothesis at a significance
level of α/m, where α is the desired overall α level (0.05) and m is
the number of hypotheses.
Kaplan–Meier survival graphs were calculated for stage,
tumor grade, histological type, weight and response, as well
as for patients who underwent surgery in combination with
immunotherapy vs. patients who did not.
For the purpose of this study, tumors were histologically
described as beingmelanotic if any part of the histological sample
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FIGURE 1 | A dog with oral malignant melanoma was presented with bone involvement and lymph node metastases and was considered refractory to surgery. (A,B)
Tumor size measurements were made with a digital caliper and documented with photography with dogs under sedation. Picture (C) shows the first injection of
AdCD40L. Picture (D) shows the second injection of AdCD40L, 7 days after first injection. Please note the rapid organization of the tumor and significantly less
necrotic tissue. The dog started eating as soon as 2 days post first injection, clearly showing an improved quality of life.
was deemed to contain pigment. Multiple tumors which were
histologically described as “mainly amelanotic” have therefore
been classified asmelanotic for the purposes of statistical analysis.
For the purpose of WHO staging, ungual and conjunctival
tumors were classified according to the protocol for dermal or
epidermal tumors, because of the lack of a universal staging
system for tumors of these locations. Patients were also grouped
according to weight and stage for statistical analyses. Weight was
divided into two groups: <20 kg (n = 17) and >20 kg (n = 15).
Similarly, patients were subdivided into three age groups: <9
years (n= 11), 9–11 years (10), and >11 years (n= 11).
When analyzing histologic cell type, groups were dived into
epithelioid, spindle shape, mixed and balloon cell (clear cell)
melanoma. Grade was divided into low and high, with mitotic
index above 2 as the determinant.
RESULTS
Patient Population
The patient population consisted of 32 dogs with spontaneously
occurring malignant melanoma: 22 oral, 5 cutaneous, 3 sub
ungual, 1 nasal and 1 conjunctival (Table 1). Patients were staged
according to the WHO staging system (36). Of the patients
included, 8 were stage I, 9 stage II, 12 stage III and 3 were stage
IV. Median age at the start of therapy was 120 months (48–
168 months). Median weight was 32.2 kg (5–49 kg). Thirteen of
the dogs were intact female, 3 were spayed females, 13 were
intact males and 3 were neutered males. Twenty of the 32 dogs
underwent surgery, 7 before immunotherapy was initiated and
13 after. Three dogs underwent surgery both prior to and after
therapy initiation. The vast majority of surgeries performed were
cytoreductive and not radical with curative intent. Two dogs
underwent a second surgery post AdCD40L immunotherapy
after initial unclean margins. At second surgery no remaining
tumor cells could be detected and the margins were clean, thus
we classified only these two surgeries as curative-intent. One dog
had undergone chemotherapy as part of previous treatment, but
tumor control had not been achieved. The number of AdCD40L
treatments ranged from 1 to 6 with a mean of 3; 15 dogs got
3 treatments and an injection volume between 0.5 and 3ml
depending on tumor volume.
Clinical Response to AdCD40L Treatment
Best overall response according to WHO response criteria,
based only on macroscopic change post immunotherapy was 7
complete response (CR), 5 partial response (PR), 5 stable disease
(SD), and 2 progressive disease (PD) (Table 1). In all cases, a
clinically evident inflammation occurred in the tumor after the
course of AdCD40L injections, with initial edema often followed
by increased firmness and signs of organization. Dogs achieving
a complete or partial response had a significantly longer median
survival (p < 0.0001) (Figure 2). Details related to survival
compared with different responses to therapy are presented in
Table 2.
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TABLE 1 | Study demographics.
Breed Age (Y) Weight (Kg) Gender Stage Grade Histologic type Treatment* BOR Time Sx Surgery Survival (Days)
Golden retriever 8 32 F III H Spindle, amelanotic 1.5ml X2 NA 9 Y 401
American cocker spaniel 11 12.5 M I L Epithelioid 1,5–3 mlX5 NA −30, 40 Y 1,141
Siberian husky 11 26.9 F I H Mixed 1 mlX6 CR 85 Y 645
Dachshund 4 5.2 F II L Epithelioid 1 mlX5 NA −35, 37 Y 3,435
Irish setter 9 37.8 M II L Epithelioid 1 mlX5 CR 81 Y 500
Golden retriever 12 32.8 F III H Balloon cell 2 mlX4 NA 16 Y 130
Mixed 13 32.4 FS III H Mixed, amelanotic 2 mlX3 NA 28 Y 180
Golden retriever 7 31 F III H Epithelioid, anaplastic 2 mlX3 NA 23 Y 279
Irish setter 12 24 F III H Epithelioid 2 mlX3 NA 25 Y 78
Mixed 11 36.5 F I L Spindle 1 mlX3 CR −30 Y 1,083
Flat coated retriever 4 37.5 M I L Epithelioid 1 mlX3 NA 15 Y 2,057
Rottweiler 5 49 M I L Mixed 1 mlX3 NA −15 Y 495
Mixed 5 35 FS I L Epithelioid (cytology) 1 mlX1 NA 15 Y 1,340
Golden retriever 12 33 M II H Mixed 1 mlX3 CR 55 Y 225
Rottweiler 8 34.5 F I L Mixed 1 mlX3 NA 35 Y 1,818
Golden retriever 14 31 M II L Epithelioid 1 mlx3 CR −30 Y 356
Labrador retriever 12 40 MC II L Spindle 1 mlx6 CR −46 Y 336
Giant poodle 14 13 FS II H Epithelioid 1 mlx3 CR 248 Y 260
Risenschnauzer 7 47 F III H Epithelioid 1 mlx2 NA −7, 400 Y 500
Mixed 12 5 MC II H Epithelioid 1 mlx3 NA 35 Y 308
Jack russel 9 7.8 M I H Spindle 1.5ml X6 PR N 290
Basset artesién 14 15.4 M IV H Mixed 0.5–2ml X3 PR N 60
Golden retriever 9 33.8 M III H Epithelioid 2–3ml X3 PD N 100
Border terrier 12 9.9 M III L Epithelioid 1ml X1 SD N 160
Flat coated retriever 8 39.6 M III H Epithelioid 2ml X5 SD N 131
Swedish lapphound 11 23 M III H Mixed 2 mlX3 PR N 48
Danish-Swedish farmdog 9 9.2 M III H Mixed 1 mlX3 SD N 128
Risenschnauzer 8 38 F IV H Mixed 2 mlX2 PD N 20
German shepherd 14 40 MC IV H Mixed 2ml X2 PR N 55
Pumi 13 11.2 FS III H Mixed, amelanotic 2 mlX2 SD N 41
Rottweiler 9 34 F II H Mixed 1 mlX4 SD N 42
Risenschnauzer 6 22 F II L Epithelioid 1 mlx6 PR N 1,211
BOR, Best overall response; CR, Complete response; PR, Partial response; SD, Stable disease; PD, Progressive disease; NA, Not Applicable. Time of surgery (Sx) in days related
to AdCD40L treatment. Some Sx were performed prior to immunotherapy. Two dogs achieved clean margins post 2nd Sx post AdCD40L treatment. *Virus concentration was 2.6 –
109 Pfu/ml.
Overall median and mean survival times were 285 and 558
days, respectively. Median and mean survival for dogs in stages
III–IV were 128 and 154 days (Figure 3). Median and mean
values for all stages are shown in Table 3. Stage was significant,
both as separate stages (p < 0.0001) with Bonferroni correction
for multiple comparisons (p < 0.008), where stage III was
prognostic, as well as where stage was grouped into low (I+II)
and high (III+IV) respectively.
Median and mean survival times for patients who
underwent surgery were 448 days (78–3,435) and 778
days respectively. For patients who did not undergo
surgery combined with immunotherapy, median and
mean survival times were 80 days (41–1,211) and 191
days respectively. Survival was significantly increased
in dogs that also underwent surgery (p < 0.0001)
(Figure 4).
Parameters significant in univariate survival analysis were
breed, age, presence of local/distant metastases, histologic grade,
tumor stage, tumor type, and surgery after therapy initiation.
These parameters were then used to stratify a Cox proportional
hazard model and significance remained for breed (Golden
Retriever) (p< 0.00001), stage (0.00006), age (dogs below 9y lived
longer) (p = 0.0119) and surgery together with immunotherapy
(0.0001). All details regarding survival with or without combined
surgery and AdCD40L treatment are shown in Table 4.
Clinical Immunology
Immunological responses, based on serum cytokine
analysis (TNF-α, IL-8, and the T-cell response
suppressor IL-10) have been reported before for 19
treated dogs, including neutralizing antibodies in
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100% post the third immunotherapy in six tested dogs
(26, 37).
In one case where a metastatic prescapular lymph node was
injected, distant immunoreaction was identified in a previously
undetected metastatic lesion in the brain. This dog developed
seizures three days after each injection with AdCD40L vector
and was euthanized one week post second injection. The CNS
metastatic lesion was examined post mortem and compared
to adjacent normal brain tissue; the metastatic lesion was
infiltrated with T-lymphocytes. The histologic findings, together
with the clinical appearance of seizures occurring three days post
injection, suggest abscopal effect of the AdCD40L injection.
Safety and Toxicity
All adverse events were recorded. Adverse reactions (considered
related to treatment) were seen in twenty out of thirty-two
dogs. Mild transient fever developed in seven, and five had
mild inappetence/anorexia. Twenty dogs had swelling at the
injection site, and this was most prominent in dogs that
received AdCD40L therapy in a metastatic lymph node. Five
FIGURE 2 | Survival plot comparing prognosis for different responses. Best
overall response according to WHO response criteria, based on macroscopic
change due to AdCD40L therapy was 7 complete response (CR; red line), 5
partial response (PR; blue line), 5 stable disease (SD; yellow line), and 2
progressive disease (PD; green line). Dogs achieving a complete or partial
response had a significantly longer median survival (p < 0.0001). Dotted line
combined group.
dogs had a mild and transient increase in liver enzymes after
treatment; one had a grade 2 increase in both alanine amino
transferase (ALT) and alkaline phosphatase, and another had
a grade 2 rise in ALT (graded according to the Veterinary
Cooperative Oncology Group Common Terminology Criteria
for Adverse Events [VCOG-CTCAE] following chemotherapy
or biological antineoplastic therapy in dogs and cats v1.1) (33).
No other adverse effects were noticed. The adverse reactions
after AdCD40L injection seemed to decline after one or two
treatments, which corresponded to an increase in adenovirus-
specific neutralizing antibodies in serum post therapy.
Due to the low toxicity and that no increase in toxicity
could be registered even when the virus titer increased up to
3ml (2.6 × 109 Pfu/ml), and that 100% of the dogs developed
neutralizing antibodies after three injections, it was decided to
use a regimen of 3 times 1ml injection, irrespective of tumor size
or number of lesions in the latter half of the trial. Exceptions were
made, where owners requested additional injections where a clear
tumor response was achieved.
Histopathology
Histological evaluation was performed in 31 dogs (one case only
diagnosed with cytology), showing 15 epithelioid melanomas,
4 spindle cell melanomas, 12 mixed type melanomas and 1
balloon cell melanoma (Table 1). The histological diagnosis of
melanoma was based on the histological classification of tumors
in domestic animals according to cytological appearance, number
of mitoses, pleomorphism, and presence of anaplastic and poorly
differentiated cells (38). However, histological evaluation alone is
not always a reliable prognostic indicator; rather the combination
of oral location andmorphology indicatingmalignancy support a
worse outcome of melanoma in dogs. In the case where diagnosis
was based on fine needle aspiration biopsy, a board-certified
veterinary clinical pathologist analyzed the cytology and the
tissue specimen was reported to contain a high frequency of
mitoses and a round cell population of markedly pigmented cells.
Thus, a tentative definition of epithelioid, high-grade malignant
melanoma was made.
Several publications report proliferation as a consistent
prognostic marker of malignant melanoma in dogs. Hence, a
grading into low and high grade was made with mitotic index
(MI) of >2 per 10 high power field (HPF) as the determinant.
With this subdivision, 12 tumors were low grade and 20 were
high grade and this was significant (p < 0.0001) (Figure 5).
TABLE 2 | Details related to survival compared with different responses to therapy in 19 dogs with macroscopic response to AdCD40L therapy.
Response Number Mean (D) Std error Median (D) Lower 95% Upper 95% p
CR 7 772* 104.6 1,083 336 · <0.0001
PD 2 60 40 60 20 100
PR 5 649* 239.7 290* 48 1,211 <0.0001
SD 5 100.2 24.7 128 41 160
Combined 19 601 97 356 160 1,211
Dogs achieving CR and PR had a significant longer survival compared to the rest of the groups. CR, complete response; PR, partial response; SD, stable disease; PD, progressive
disease; *significant p < 0.008, Bonferroni correction for multiple comparisons.
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FIGURE 3 | Survival plot (A) all stages (B) Stages I+II (red) and III+IV (blue). Dotted line combined group.
TABLE 3 | Comparison of survival between different stages.
Stage N Mean Std error Median (D) Lower 95% Upper 95% p
I 8 1108.6 220.4 1,112 290 1,818
II 9 741.4 354.0 336 42 1,211
III 12 181.3 41.1 131¤ 48 279 0.0001
IV 3 45 12.6 55 20 60
I+II 17 914.2 212.8 500 290 1,211
III+IV 15 154.1 35.7 128* 48 160 0.0001
Combined 32 558 131.6 285 130 495
Stages also merged in low (I+II) and high (III+IV) to equal group size. Survival was significantly lower in stage III compared to all other groups. When only comparing low (I+II) and high
(III+IV) stage, it was a significantly worsened prognosis in high stage. ¤Significant, p < 0.008, Bonferroni correction due to multiple comparisons. *Significant, p < 0.05.
FIGURE 4 | Survival plot comparing AdCD40L immunotherapy only (n = 12,
red line), median 80 days and combined with surgery (Sx) (n = 20, blue),
median 448 days. Survival was significantly longer in dogs that also underwent
surgery combined with immunotherapy p < 0.0001. Dotted line combined
group.
For full details of survival data in different histology grades,
see Table 5. Immune activation by AdCD40L therapy was seen
in several of the patients. An increase in the infiltration of
immune cells was seen in 8 of 11 dogs. Histological grading
described in (26) was based on lymphocyte counts of random
representative areas in the tumors, and defined as: none = 0, 1–
10 lymphocytes per high power field = 1, 11–30 lymphocytes
per high power field = 2, and >30 lymphocytes per high
power field = 3. Tumor regression was seen histologically in
25 of 32 cases. There was an initial significant relationship
between histological tumor type and overall survival, with
the mixed type showing a worse outcome (p < 0.035),
although with Bonferroni correction for multiple comparison
(p < 0.008) this significance was lost (Figure 6). Details of
the outcome depending on histologic type are presented in
Table 6. No statistical significance was seen in the relation
between the increase of immune cell infiltration after treatment
and overall survival. A comparison was made on survival
depending on melanotic (n = 25) or amelanotic (n = 7). No
statistical difference on survival between the groups were seen
(p < 0.11).
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TABLE 4 | Comparison of survival between dogs only treated with immunotherapy and dogs also undergoing surgery.
Group N Mean (D) Std error Median (D) Lower 95% Upper 95% p
AdCD40L only 12 191 95.2 80 41 160
Surgery plus AdCD40L 20 778 187.8 448* 260 1,083 <0.0001
Combined 32 558 131.6 285 130 495
Survival was significantly longer in dogs that also underwent surgery combined with immunotherapy (p < 0.0001). *Significant, p < 0.05.
FIGURE 5 | Survival plot: low grade (red line, n = 12) vs. high grade (blue line,
n = 20) (p < 0.0001). Dotted line combined group. Survival was significantly
lower in high grade disease.
DISCUSSION
We describe responses, overall survival and toxicity in a large
group of dogs with a single tumor type, where there still is an
unmet need regarding treatment modalities. Reported median
survival time for dogs with stage II melanoma treated with
curative intent surgery alone is less than five months, and in
dogs with grade III or IV it is less than two to three months
(1, 3, 39). In the current study, median survival for dogs in
all stages was 285 days, whilst for dogs in stage II it was 336
days, and for stages III–IV was 128 days. Although this was not
a randomized study aiming at proving efficacy, these survival
times compare favorably to the previously reported figures.
This suggests that AdCD40L immunotherapy has potential
value in therapy of canine malignant melanoma CMM, either
as adjuvant in a multimodal treatment setting, or for use as
a primary therapy form when alternatives are not feasible.
Finally, surgeries performed in this study were cytoreductive. In
contrast to radical surgery, partial removal of the tumor leads
to rapid recurrence locally, with short subsequent survival (39).
The addition of AdCD40L immunotherapy as a consolidating
therapy allowed survival comparable to situations when radical
surgery is possible. Importantly, in contrast to radical surgery,
immunotherapy plus cytoreductive surgery allowed high quality
of life and functioning, with only mild and transient adverse
reactions. Hence, the results encourage further investigation
of the potential of adenoviral gene therapy in dogs with
malignant melanoma.
Many different immunotherapy studies in canine malignant
melanoma have been published (40). As many different
techniques and case selection are involved, comparisons are
hard to conduct. Different methodologies for gene transfer
has been tested, such as CSPG4 (41), xenogenic Tyrosinase
(42) and hgp100 (43). Collectively, macroscopic responses to
immunotherapy are modest, but toxicity are tolerable and usually
overall survival is reported to be favorable when combining with
other therapies, preferentially surgery. To our knowledge, our
studies are still the only one reporting responses in naturally
occurring malignant melanomas in dogs using oncolytic viral
therapy, although the technique is considering a promising
modality also in dogs and many in vitro studies have been
conducted (44, 45). The long-follow up time in this study is a
strength and also rather unique, but comparable with at least
one gene therapy clinical trial with a similar long-term follow-
up published in the field (46). Oncolytic viral treatment in other
canine malignancies are also reported (47).
A single pathologist (T.S.) reviewed the majority, but not
all of the tumors. Since some of the tumors could not be re-
evaluated, interpretation was done using the original histology
reports. Currently, there is no consensus grading of canine
malignant melanoma. Ramos-Vara and colleagues made the
most promising attempt in 2000, using 338 oral malignant
melanoma cases (38). Here several prognostic features were
reported, and a score was described. Both in this study and
as previously reported, proliferation stands out as a fairly
robust prognostic indicator, where a mitotic index (MI) >2
is reported to shorten overall survival in many different types
of malignant melanomas regardless of anatomic location (3,
38, 48). We therefore grouped the tumors into low and high
grade if proliferation was reported to be MI >2. With this
rather simple categorization, grade was prognostic with a median
overall survival (OS) of 1,112 days with low-grade and only 131
days with high-grade tumors. One tumor was only diagnosed by
cytology, but as the tumor was examined by a board-certified
veterinary clinical pathologist and had so many cytological
features of a high-grade malignant melanoma (and many visible
mitotic figures), it was classified as an epithelioid high-grade
malignant melanoma.
At least one clear case of abscopal effects of distant
reaction in a CNS metastatic lesion was registered in the
study. In future prospective studies with stronger funding
allowing e.g. more frequent use of advanced digital imaging,
the true occurrence of abscopal effect can be verified in
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TABLE 5 | Comparison of survival between different histologic grades.
Histology grade N Mean (D) Std error Median (D) Lower 95% Upper 95% p
Low 12 1,161 270.5 1,112 336 1,818
High (MI) >2 20 196.1 37.9 131* 55 279 <0.0001
Combined 32 558 131.6 285 130 495
Survival was significantly lower in the cases with a high mitotic index. *Significant, p < 0.05.
dogs with melanoma treated with AdCD40L therapy.
Comparing the OS data in this study with historic controls,
especially as many dogs received no other treatment than
immunotherapy for macroscopic malignant melanoma, the
likelihood of abscopal effects in more dogs is, however,
very high.
In human oncology several clinical trials have been conducted
with AdCD40L therapy, prior to radical surgery (22, 49).
(22, 49). Here, reference to the current dog study is of
comparative value, as many of the dogs did not receive
any surgery at all and the vast majority of those did not
undergo radical surgery. These two factors have been reported
to significantly worsen prognosis in dogs (39). A clinical
trial with 15 treatment-refractory patients with malignant
melanoma received intratumoral injections of AdCD40L (28).
Nine of the patients also received low-dose cyclophosphamide
conditioning before the first and fourth AdCD40L injection.
As in dogs with malignant melanoma, the side effects were
few with mild transient reactions. No macroscopic objective
responses were recorded by MRI, but local and distant
responses were seen on FDG-PET. Survival at six months
appeared improved when cyclophosphamide was added to
AdCD40L. The patients with the best survival developed
the highest levels of activated T cells and experienced a
pronounced decrease of intratumoral IL8. The results are
encouraging for proceeding with adenoviral and CD40 directed
treatment modalities.
No dogs were treated with immune interfering medication
before AdCD40L injections. This enables a clean description
of toxicity, but also the true efficacy of injections alone.
Based on current understanding within immuno-oncology, the
initial suppression of e.g. Tregs will potentiate the following
immune therapy given. In one study, Mitchell and colleagues
reported that the veterinary-registered TKI toceranib (Palladia,
Zoetis, USA) had similar reduction potential of Tregs as
classic low-dose cyclophosphamide (50). Toceranib is a multi-
kinase inhibitor, closely related to sunitinib (51). The use
of toceranib, as a conditioner in association with immune
therapy in cancer patients, would also promote an antagonistic
action toward VEGF, as well as add to the collective action
to tilt the inflammatory environment in the tumor toward
a less angiogenic environment with fewer immunosuppressive
lymphocytes and more Th1 cells and M1 macrophages (1, 3, 38,
52–56).
The parameters found to be significant in association with
OS were: Breed, Age, Stage, Grade, and Surgery together
with immunotherapy.
FIGURE 6 | Survival plot comparing prognosis in different histological groups.
Epithelioid (n = 15, red line), spindle type (n = 4, green line), mixed type (n =
12, blue line) and one balloon cell (clear cell) melanoma. Dotted line combined
group. Mixed cell type had a p-value of p < 0.035, which was not considered
significant when addressing the Bonferroni correction for multiple comparisons
(p < 0.008).
Stage being a significant parameter complies with earlier
reports (1–3). Considering that stage is a widely used prognostic
tool it was expected that a correlation between stage and OS
would be observed. This supports the validity of the WHO
staging system as a prognostic tool. An expanded, revised staging
system has been suggested, withmore prognostic factors included
(39). Herein the need to compensate for body weight is suggested,
as a primary tumor with a diameter of 4 cm in a small-sized dog
of 5 kg should be considered worse than the same tumor size
in a dog weighing 40 kg. In our study we found a trend toward
survival benefit for dogs weighing >20 kg (median OS of 495
vs. 225 days), although this was not statistically significant. If
the study had been larger, the possibility of this finding being
significant would likely increase. On the other hand, it is reported
that increased bodyweight is negatively correlated with longevity
in dogs (57).
Breed has also been shown in one previous study to be
associated with OS (58). The most common breed in this study
was the Golden Retriever, making up 6 of 32 patients, supporting
the suggestion that this breed is particularly predisposed to
CMM (38), although the patient group cannot be considered
representative of the population as a whole because of the
small sample size. No conclusions can be drawn in regard
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TABLE 6 | Comparison of survival between different histologic types.
Histology type N Mean (D) Std error Median (D) Lower 95% Upper 95% p
Epithelioid 15 790 240.5 356 131 1,141
Spindle 4 528 186.6 369 290 1,083
Mixed 12 313 148.3 94 41 495 0.035
Balloon cell 1 130 0 130 0 0
Combined 32 558 131.6 285 130 495
The initial deceased survival detected in the mixed group was lost when using Bonferroni correction (p < 0.008) for multiple comparisons. MI, Mitotic index.
to specific breeds’ positive or negative correlations with OS,
although an unpowered significant difference was observed due
to the fact that there were in most cases only one or two patients
representing each breed.
Age was correlated to OS as dogs below 9y lived longer (p =
0.0119; Bonferroni correction (p < 0.012), when the dogs were
categorized into three equal sized groups; <9, 9–11 and >11
years. Younger dogs have fewer co-morbidities and owner’s may
be more prone to invest in advanced treatments for younger
animals. Still the significance is borderline and not interpreted
as a major finding in this study.
Surgery showed a positive correlation with OS. This result
may, however, be biased, for a number of reasons. Unfeasibility
of radical surgery was one of the entry criteria for the clinical
trial, emphasizing the exceptionally long survival time observed
in the study. Whether or not a dog underwent surgery as part
of treatment at a later stage may also have been influenced by
a number of factors including the owners’ personal feelings,
age of the dog, previous treatment history, financial situation,
etc. However, our results suggest that cytoreductive surgery may
be useful in combination with immunotherapy for achieving
the best results. The underlying mechanism may relate to the
immunosuppressive nature of large tumors, partly conducted
through tumor exosomes and generation of a pre-metastatic
niche (59). Physically removing some of the immunosuppressive
mass may facilitate the long-term effects of immunotherapy.
Tumors were staged according to the WHO staging scheme
(36). The WHO staging, with a few exceptions, is divided into
localization-specific tumor protocols. This study included tumors
originating from cutaneous, oral, nasal, conjunctival and ungual
tissue. However, due to a lack of specific protocol for conjunctival
and ungual tumors according to the WHO staging scheme,
these tumors were staged according to the criteria for dermal or
epidermal tumors.
Spontaneous tumors in dogs have been suggested as
good comparative models to human cancers. They occur
spontaneously, in immunocompetent animals, often have similar
or identical histologic appearance, share metastatic preferences
and pattern, respond to the same type of treatment protocols
(surgery, chemotherapy, radiotherapy and immunotherapy) and
share the same environment as their owners (60–63). The
pet dog has also been suggested as a good model to inform
drug development and cancer treatment trials in humans (64).
The comparative aspects of malignant melanoma in dogs have
been extensively reviewed, showing both molecular biological
similarities and thanks to a spontaneous developing tumor in an
immune competent animal, ideal for investigating new treatment
modalities, especially immunotherapy (10, 11, 14, 65). Finally, the
rapidly increasing resolution of the dog genome sequence makes
canine comparative oncology studies easier to perform with high
accuracy (66).
The findings in this study, with encouraging survival data,
low toxicity and the achievement of good quality of life during
and post treatment in such a complicated tumor in dogs,
supports the usefulness of the canine melanoma model for
developing and informing parallel clinical studies in humans with
malignant melanoma.
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